ADME
Sponsors
Acacia Pharma, Novartis Pharma AG, Actelion Pharmaceuticals, Inc., Bial Portela & Ca.
Conditions
cardiovascular diseaseshypertension
PAHmisselijkheid en braken
nausea
vomitingneuralgia
peripheral neuropathic pain
Unknown Phase
An open label, single dose, single period study to assess the mass balance recovery, metabolite profile and metabolite identification of [14C] APD421 administered via the intravenous route to healthy male subjects
Active, not recruitingNL-OMON42878
Start: 2016-07-13Target: 6Updated: 2024-02-28
Single-center, open-label study with 14C-radiolabeled ACT-132577 to investigate the mass balance, pharmacokinetics, and metabolism following single oral administration to healthy male subjects.
Active, not recruitingNL-OMON45381
Start: 2017-03-08Target: 6Updated: 2024-02-28
An open-label study to assess the absorption, distribution, metabolism and excretion, including the mass balance of [14C] labeled BIA 5-1058 and metabolites following a single oral dose administration in healthy male subjects
Active, not recruitingNL-OMON45578
Start: 2017-03-31Target: 8Updated: 2024-02-28
A single-center, open-label, single oral dose study to investigate the absorption, distribution, metabolism, and excretion (ADME) and pharmacokinetics of EMA401 after a single dose of [14C]EMA401 in healthy male subjects
Active, not recruitingNL-OMON44485
Start: 2017-07-27Target: 6Updated: 2024-02-28